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Abstract
Background—Many neurobiological factors may initiate and sustain alcoholism. Recently,
dysregulation of the neuroimmune-system by chronic-ethanol (CE) has implicated toll-like
receptor-4 (TLR4)-activation. Even though TLR4s are linked to CE-initiation of brain cytokine-
mRNAs, the means by which CE influences neuroimmune signaling in the sterile environment of
brain remains uncertain. Therefore, the hypothesis is tested that release of an endogenous TLR4
agonist, high-mobility group box 1 (HMGB1) and/or CRF during CE-withdrawal are responsible
for CE-protocols increasing cytokine-mRNAs.
Methods—Acute-ethanol 2.75g/kg) and acute-LPS (lipopolysaccharide)(250μg/kg) dosing on
cytokine-mRNAs are first compared. Then, the effects of chronic-LPS exposure (250 μg/kg for
10-days) on cytokine-mRNAs are compared to changes induced by CE-protocols [15-days of
continuous 7% ethanol-diet (CE-protocol) or three-intermittent 5-day cycles of 7%-ethanol-diet
(CIE-protocol)]. Additionally, TLR4-, HMGB1- and down-stream effector mRNAs are assessed
after CE, CIE, and chronic-LPS. To test whether HMGB1 and/or CRF support the CE-withdrawal
increase in cytokine-mRNAs, the HMGB1-antagonists, glycyrrhizin and ethyl-pyruvate, and a
CRF1-receptor-antagonist (CRF1RA) are administered during 24-hours of CE-withdrawal.
Results—While cytokine-mRNAs were not increased following acute-ethanol, acute-LPS
increased all cytokine-mRNAs 4-hours after injection. CE produced no change in cytokine-
mRNAs prior to CE-removal; however, the CE- and CIE-protocols increased cytokine-mRNAs by
24-hours after withdrawal. In contrast, chronic-LPS produced no cytokine-mRNA changes 24-
hours after LPS-dosing. TLR4-mRNA was elevated 24-hours following both CE-protocols and
chronic-LPS exposure. While chronic-LPS had no effect on HMGB1-mRNA, withdrawal from
CE-protocols significantly elevated HMGB1-mRNA. Systemic administration of HMGB1-
antagonists or a CRF1RA significantly reduced the cytokine-mRNA increase following CE-
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withdrawal. The CRF1RA and the HMGB1-antagonist, ethyl-pyruvate, also reduced the HMGB1-
mRNA increase that followed CE-withdrawal.
Conclusion—By blocking HMGB1 or CRF action during CE-withdrawal, evidence is provided
that HMGB1- and CRF-release are critical for the CE-withdrawal-induction of selected brain
cytokine-mRNAs. Consequently, these results clarify a means by which withdrawal from CE-
exposure activates neuroimmune-function in the sterile-environment of brain.
Keywords
Chronic-Ethanol Withdrawal; LPS; Cytokines; HMGB1-Antagonists and CRF1-Receptor
Antagonist
Introduction
Although alcohol abuse influences many organs throughout the body, its effect on the brain
represents the most significant component in the maintenance of alcoholism. In spite of
numerous factors having previously been implicated in initiating and sustaining alcohol
abuse, dysregulation of the neuroimmune system has recently come to light as playing a
significant role in the consequences of chronic-ethanol-(CE) exposure (Alfonso-Loeches et
al. 2010; Breese et al., 2008; Crews et al., 2011, 2012; He and Crews 2008; Knapp et al.,
2011; Pascual et al., 2007; 2011; Qin et al., 2008; Valles et al., 2003). Further, recent
experimental studies have demonstrated a key link between ethanol and activation of the
neuroimmune system via toll-like receptor-4 (TLR4) signaling (Akira and Takeda, 2004;
Alfonso-Loeches et al. 2010; et al., 2005; Fernandez-Lizarbe et al., 2008; 2009; Wu et al.,
2012; Zou and Crews, 2010).
Crews et al. (2012) found increased expression of TLR4 in post-mortem human alcoholic
frontal cortex as well as in brain of mice following CE-exposure. Several additional studies
in TLR4-KO mice have supported a role for TLR4 signaling in ethanol-induced increases in
cytokine production—evidence which includes preventing ethanol-induced liver injury
(Uesugi et al., 2001), ethanol activation of TLR4 signaling in cells (Blanco et al., 2005;), the
inflammatory gene expression induced by ethanol in mice (Alfonso-Loeches et al., 2010;
Fernandez-Lizabre et al., 2008, 2009), neurodegeneration induced by CE-intake (Alfonso-
Loeches et al., 2010), involvement in seizure sensitivity (Maroso et al., 2010), antagonism of
the sedation and motor impairment associated with acute-ethanol administration (Wu et al.,
2012), and antagonism of the behavioral impairment induced by CE-exposure (Pascual et
al., 2011). Collectively, these studies provided convincing evidence that TLR4s contribute to
the CE-mediated increase in brain cytokines that contribute to behavioral and pathological
changes associated with CE-exposure.
Fernandez-Lizarbe et al. (2008) provided evidence that low to moderate concentrations of
ethanol facilitate recruitment of TLR4s into lipid rafts that results in TLR4 activation,
similar to lipopolysaccharide (LPS) (Triantafilou et al., 2002). While the LPS-agonist-action
on TLR4s (Okun et al., 2009) is used to model bacterial infections, ethanol is unlikely to
induce brain cytokine-mRNAs by directly activating TLR4-signaling. Rather, ethanol,
unlike LPS (Pålsson-McDermott and O’Neill, 2004), most likely influences TLR4 in the
sterile environment of brain by either releasing an endogenous agonist for TLR4s (Crews et
al, 2012) or by CRF release during withdrawal from CE-exposure (Breese et al., 2011).
Therefore, to determine if ethanol and LPS have similar properties, the present investigation
first compares the acute- and chronic actions of LPS with acute-ethanol and CE-protocols on
mRNAS for cytokines, TLR4, HMGB1 [i.e., High-mobility group box-1; Andersson and
Tracey, 2011), an endogenous TLR4 agonist. Subsequently, a CRF-receptor antagonist
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(Knapp et al, 2004) and two HMGB1-antagonists (Mollica et al., 2007; Ohnishi et al., 2011;
Su et al.,2011) are used to test the hypothesis that in the sterile-environment of brain
(Andersson and Tracey, 2011) release of CRF and/or HMGB1 during CE-withdrawal is
responsible for increasing brain cytokine-mRNAs (Breese et al., 2011; Fernendez-Lizarbe et
al., 2008; Yang et al., 2005). 502
Materials and Methods
Animals
Adult male Sprague-Dawley rats obtained from Charles-River (Raleigh, NC) weighed
180-200g upon arrival. Subsequently, rats were group housed and fed RMH3000 rat-chow
(TestDiets, Richmond, IN) for 2-3-days to acclimate them to the new environment
(temperatures 70-72° F; humidity 40-60%; and a 12hr-light/12hr-dark cycle) prior to study
initiation. Then, all animals were singly housed for acute and chronic-ethanol and LPS-
exposures. All methods used were approved by the University of North Carolina—Chapel
Hill’s Institutional Animal Care and Use Committee.
TREATMENT PROTOCOLS
Liquid Diet
A nutritionally-complete and calorically-balanced liquid diet for control (CD) and the
chronic-ethanol diet (CE)-protocol were used with adjustments made in the amount of
dextrose added to each diet type, as previously described (e.g., Frye et al., 1983; Knapp et
al., 2004; Overstreet et al., 2002; Wills et al. 2008). Rats were fed either control diet or 7%
thanol (wt/vol) in a modified pair-feeding system to balance diet intake.
Acute-LPS and Acute-Ethanol Protocols—Either a single 250 μg/kg dose of LPS
(E.coli 0111;B4) (Calbiochem & EMD Chem Inc, San Diego, CA) or saline-vehicle was
injected intraperitoneally (IP) to rats that were sacrificed 4-hours later (Fig 1B). For
comparison with LPS, oral gavage of either a single 2.75 g/kg ethanol-dose or tap water to
controls was utilized (Fig. 1A). For the oral-ethanol dose, peak blood alcohol levels of
185-200 mg% were observed, as found previously (Overstreet et al., 2002; Wills et al.,
2008). Four-hours following either acute-ethanol or acute-LPS dosing, rats and
corresponding controls were sacrificed and brains collected for assessment of cytokine and
TLR4-mRNAs and selected cytokine-peptides.
Chronic-LPS Protocol—Chronic-LPS (E.coli 0111;B4) effects on cytokine function
were determined after 10-daily injections of LPS (250 μg/kg, IP) (Fig 1D). Controls
received saline-injections daily for 10-days. Animals were sacrificed and brains harvested
24-hours following final injection for analysis of mRNAs for cytokines, TLR4, HMGB1,
MyD88 (myeloid differentiation factor-88; Janssens and Beyaert, 2002) or NF-Kb-(nuclear
factor-κ-light-chain-enhancer of activated B cells; Baeuerle and Henkel, 1994; Fitzgerald et
al., 2003).
Continuous (CE) and Intermittent Chronic-Ethanol (CIE) Protocols—The CE-
protocol involved 15-continuous days of ethanol liquid diet (7% wt/vol) (Frye et al., 1983)
(Fig 1C) and the CIE-protocol involved three 5-day bouts of ethanol-diet separated by 2-
days of control diet (Overstreet et al., 2002; Fig 1F). To determine if a difference between
the CE- and CIE-exposures occurred, rats were sacrificed 24-hours after withdrawal from
each protocol. As before, brains from these groups were collected and processed for mRNAs
for cytokines, TLR4, and HMGB1 and other neuroimmune elements. To determine the peak
brain cytokine, TLR4 and HMGB1-mRNA production and duration of change for the CE-
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protocols, animals were sacrificed 24-, 48-, 72-hours and 7-days following withdrawal (Fig.
1E). These brains were collected and processed for cytokine, TLR4, HMGB, myD88 (-
mRNAs.
Brain Tissue Collection
All brains were collected following rapid decapitation. Whole brains were extracted and
immediately frozen in isopentane at −25° C prior to storage at −80° C for later
microdissection of the cortex. Cortical tissue was divided into two halves to provide tissue
for qPCR as well as for selected ELISA determinations.
Administration of a CRF1-Receptor antagonist (CRF1RA) and HMGB1-
Antagonists During CE-Withdrawal—To test whether CRF and/or HMGB1 were
involved in increasing cytokine-mRNAs during CE-withdrawal, antagonists for both were
administered IP 4- and 12-hours during the 24-hour period of withdrawal from CE-exposure.
The CRF1RA (CP-154,526; 10mg/kg) suspended in 0.5%-carboxymethylcellulose was used
to block CRF action (Knapp et al., 2004). To test for a role of HMGB1 in cytokine-mRNA
increases after the CE-protocol, the HMGB1-antagonists, [either glycyrrhizin ammonium
salt (50 mg/kg) (Sigma, St.Louis, Mo) or ethyl-pyruvate (75 mg/kg) (Sigma, St. Louis, Mo)]
were also administered IP 4- and 12-hours during CE-withdrawal. All control subjects
received injections of sterile saline IP. To block HMGB1 function, glycyrrhizin acts to
prevent released HMGB1 from acting on TLR4 (Girard, 2007; Mollica et al., 2007; Ohnishi
et al., 2011), whereas ethyl pyruvate interferes with HMGB1 function by minimizing its
release (Dave et al., 2009; Su et al., 2011).
Real-Time RT-PCR Analysis for mRNA—Total RNA was extracted from homogenized
micro-dissected cortex from control and CE-ethanol-treated groups and LPS-exposed rats
using Trizol (Invitrogen, Carlsbad, CA). RNA was converted to cDNA utilizing RT/PCR as
described elsewhere (Qin et al., 2008). SYBR green PCR master mix (Applied Biosystems,
Foster City, CA) was used for real-time PCR analysis. The cycle time (CT) values were
normalized with β-actin to assess relative differences of mRNA expression between groups.
Calculated values were expressed as relative change compared to controls set as 100%.
Primer sequences for all mRNA determinations are shown in Table 1.
ELISA Determination of Cytokine-Peptides—Cortical samples were collected as
described in the Brain-Tissue Collection section 4-hours after acute-ethanol, acute-LPS or
24-hours after CE-withdrawal. These tissues were homogenized in Iscove’s Modified
Dubecco-Medium (Invitrogen, Carlsbad, CA) containing a Complete-protease-inhibitor
cocktail (Roche Diagnostics, Indianapolis, IN). Homogenized specimens were centrifuged
10 min at 12,000g (4°C). Supernatants collected were stored at −80°C until cytokine-
peptides were determined. ELISA kits for the determinations were purchased for IL-1β and
TNF-α from R&D Systems (Minneapolis, MN), for CCL2 from BD BioSciences (San Jose,
CA), and for HMGB-1 from IBL-International (Hamburg, Germany). CCL2 standard was
diluted according to kit instructions, but standards for IL-1β and TNF-α were serially diluted
to a specificity of 1.95 pg/ml and 0.78 pg/ml, respectively. Other ELISA procedures were
performed according to manufacturer’s directions. All cytokine-levels were corrected by
protein concentration calculated using Pierce® BCA Protein assay (Thermo Scientific,
Rockford, IL).
Statistical analysis
Data (expressed as mean ± SEM) were evaluated for statistical significance with either the
student’s t-test or ANOVA with Fishers Least Significant Difference (LSD) tests for
individual comparisons of group pairs as appropriate. Individual data points that were three
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standard deviations from their respective group means were removed from the group prior to
analysis. P-values<0.05 were considered statistically significant.
RESULTS
Comparison of Acute-Ethanol with Acute-LPS on Cytokine-mRNAs and Cytokine-Peptides
Acute-ethanol versus acute-LPS effects on cytokine-mRNAs and corresponding cytokine-
peptides were determined four-hours after treatments. The acute-ethanol (2.75 g/kg) induced
no significant change in CCL2, IL1-β, and TNFα mRNAs (Fig. 2A). Likewise, when
additional rats (n=12) were assessed 24-hours following acute-ethanol, no changes in
mRNAs for these cytokine-mRNAs were found (Fig 2 legend). Further, no TLR4-mRNA
change was observed at either 4-(Fig 2C) or a24-hours (Fig. 2 legend) after acute-ethanol
exposure. When cytokine-peptides were assessed 4-hours after acute-ethanol, levels of
CCL2 and IL1-β-peptides were not changed, but the TNFα-peptide was significantly
increased (Table 2). In contrast to acute-ethanol, an acute-dose of LPS (Fig 1B) caused a
several-fold increase in the mRNAs for CCL2 (432%), IL1-β (337%), and TNFα (920%) 4-
hours after dosing (Fig 2B). However, the acute-LPS dose did not significantly alter TLR4-
mRNA (Fig. 2D). Whereas acute-LPS increased CCL2 and IL1-β-peptides 4-hours after
exposure (Table 2), TNFα-peptide was not increase (Table 2). In a second investigation,
LPS alternatively induced a significant increase in the TNFα-peptide (Table 2-legend). An
explanation for these varying responses for the TNFα-peptide after acute-LPS was not
apparent.
Collectively, these results for acute LPS and acute-ethanol on cytokine-mRNAs and tissue
cytokine levels provides a clear distinction between acute-ethanol and acute-LPS
administration on neuroimmune responsiveness. Regardless, because a comparable
concordance in cytokine-peptide change to that for cytokine-mRNAs was not observed for
either of the acute treatments, this lack of agreement is a clear alert that more must be
learned about the biological control by which brain cytokine-peptides are synthesized from
their corresponding mRNAs.
Comparison of a Chronic-Ethanol Protocol with Chronic-LPS on Cytokine-mRNAs
To assess for potential cytokine-mRNA differences between the CE-protocol and chronic-
LPS exposure (see Figs IC & 1D-schematics), measures of cytokine-mRNAs were
determined 24-hours following withdrawal from each. After CE-withdrawal, mRNAs for all
cytokines showed significant increases compared to control (CCL2=144.9%; IL1-β=97.3%;
TNFα=125%; Fig. 3A). In contrast to these increases induced by the CE-exposure, no
significant increases in CCL2-, IL1-β-, and TNFα-mRNAs were observed after the last
chronic-LPS dose (Fig. 3B). Thus, this comparison of CE- and chronic-LPS-exposure on
brain cytokine-mRNAs provided further evidence for distinct influences being present for
LPS and ethanol.
Comparison of CE-Exposure Versus Chronic-LPS Treatment on TLR4, HMGB1, myD88,
and NF-κB mRNAs
After finding increased cytokine-mRNAs following CE-exposure and the chronic-LPS
treatments, the effect of CE and chronic-LPS on mRNAs for TLR4, HMGB1 and other links
to TLR4 function were ascertained (Fig 4). Interestingly, a significant increase in TLR4-
mRNA was found after 24-hours of withdrawal for both the CE-exposure (63.3% increase)
and the exposure to chronic-LPS (79.2% increase) (Fig 4A & 4B), without an observed
differences between these groups (p>0.05). Thus, this lack of difference between the CE-
and chronic-LPS protocols in the TLR4-mRNA increase provided no further evidence for a
distinction between ethanol and LPS action.
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Subsequently, a test of whether a change in HMGB1-mRNA would be observe for the CE
and chronic-LPS treatments was undertaken. Whereas CE-exposure significantly elevated
HMGB1-mRNA by 102.8%, the chronic-LPS did not alter HMGB1-mRNA (Figs 4C & 4D).
Further, neither the CE-protocol nor the chronic-LPS protocol induced a significant change
in the MyD88- or NF-Kb-mRNAs (Fig 4G & 4H), both of which are linked to TLR4
function (Fig 4E & 4F). Consequently, these data on the induction of HMGB1-mRNA by
CE-exposure and chronic-LPS provided another distinction between the action of ethanol
and LPS.
Time-Course of Cytokine-mRNAs Following CE-Withdrawal
Upon finding that cytokine-mRNAs increased 24-hours after CE-exposure (Fig 3), mRNA-
expression was next determined for cytokine-mRNAs at various times (0, 1, 3, and 7-days)
after withdrawal from CE (Fig. 5A). No significant change was observed in cytokine-
mRNAs in rats sacrificed while still exposed to alcohol drinking (i.e., T=0). However, in
confirmation of previous cytokine-mRNA data after the CE-exposure (Fig 3), mRNA
expression significantly increased by 102% for CCL2, by 93.8% for IL1-β, and by 107% for
TNFα 24-hours after CE-withdrawal (Fig 5A). Subsequently, by 3-days cytokine-mRNAs
gradually declined with changes being approximately 68% for CCL2, 1.0% for IL1-β and
61% for TNFα above control (Fig. 5A). By 7-days, these cytokine-mRNAs returned to
control levels. Thus, these findings confirm that the increases in CCL2, IL1-β, and TNFα-
mRNAs following 24-hours of abstinence from CE-exposure results in time-dependent
changes over the 7-day period.
Time Course of TLR4- and HMGB1 mRNA Changes Following CE-Exposure
Because TLR4 and HMGB1-mRNA expression was elevated after removal from CE-
exposure (Fig 4), the time course for TLR4- and HMGB1-mRNAs changes were also
determined (Fig 5B). Prior to ethanol withdrawal (T=0), the TLR4-mRNA level was not
significantly different from control. However, with 24-hours (1-day) of CE-withdrawal, the
TLR4-mRNA had significantly risen by approximately 68% (Fig 5B), consistent with data
in Fig 4B. By 72-hours (3-days) after CE-withdrawal, TLR4-mRNA fell to control levels
and by 7-days the TLR4-mRNA dropped to 81% below control (p<0.05; Fig 5B).
Prior to ethanol-diet removal (T=0) the level of HMGB1 mRNA was significantly elevated
by 35% above control (Fig. 5.B). However, in a second experiment, this HMGB1-mRNA
increase was not found to be altered at T=0 (p>0.05; see Fig 5 legend). Regardless, in
agreement with Fig. 4B, the HMGB1-mRNA had significantly increased by 119% above
control by 24-hours (Fig 5B). Subsequently, similar to TLR-mRNA, HMGB1-mRNA levels
dropped to control levels by 72-hours after CE-withdrawal and by 7 days fell to 88% below
control (p<0.05; Fig 5B). Thus, a distinct difference was observed in the changes in TLR4
and the HMGB1-mRNAs over time compared to the alterations observed for the cytokine-
mRNAs after withdrawal from the CE-exposure.
CE- or Chronic-Intermittent-Ethanol (CIE) Exposures on Cytokine-mRNAs and the CE-
Exposure on Cytokine-Peptides
We previously reported that withdrawal from the CIE-protocol (cycled ethanol; Fig 1F)
increased seizure-susceptibility and anxiety-like behavior to a greater degree than did a
comparable continuous-CE-protocol (McCown and Breese, 1990; Overstreet et al., 2002), a
distinction which prompted determining if a divergence in the expression of cytokine-
mRNAs would be observed 24-hours after withdrawal from these differing CE-protocols.
This assessment (Fig 6) found that cytokine-mRNAs significantly increased after
withdrawal from the CE-exposure (i.e., CCL2=79.8%; IL1-β=102.3%; TNFα=96.2%) and
the CIE-exposure (i.e., CCL2=70.5%; IL1-β=82.0%; TNFα=108.4%), but a statistical
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difference between these two exposures was not present. Unlike the increase in cytokine-
mRNAs after withdrawal from CE-exposure (Fig 6), cytokine-peptide values determined 24-
hours after the CE-protocol exposure did not demonstrate a significant change (Table 3).
Effect of the CE- and CIE-Protocols on mRNAs for TLR4, HMGB1, My88, and NF-κB
Further evaluation of the two-protocols revealed that TLR4-mRNA for the CE-(122.6%) and
CIE-(85.2%)-protocols were significantly increased (Fig. 7A), but these increases for these
exposures also did not differ (p>0.05). The HMGB1-mRNA for both the CE- and the CIE
protocols 24-hours following withdrawal was also significantly increased (CE=64.4%;
CIE=57.3%; Fig. 7B), but these increases also were not significantly different (Fig 7B).
Finally, analysis of MyD88 and NF-κB-mRNAs determined no significant change for either
of these measures in these CE-exposed groups (Fig 7C & 7D). Thus, both the CE- and CIE-
groups increased mRNA expression for cytokines, TLR4 and HMGB1 to an equivalent
degree without affecting mRNAs for My88 or NF-κB 24-hours after withdrawal.
Effect of a CRF1RA Antagonist and HMGB1-Antagonists on Cytokine- and HMGB1-mRNA
Increases Following CE-Withdrawal
To determine if an upstream-influence of CRF-release was contributing to the elevation in
cytokine-mRNAs during the 24-hours of CE-withdrawal, a CRF1RA was initially
administered twice during the withdrawal from CE-protocol (Fig 1G-schematic). This
CRF1RA-treatment significantly reduced the increase in the mRNAs for CCL2, IL1β, and
TNFα that followed withdrawal from the CE-exposure (Fig 8). Subsequently, based upon
the hypothesis that HMGB1 was involved in the cytokine-mRNA increases, administration
of the HMGB1-antagonist, ethyl-pyruvate (Su et al, 2011) twice during the 24-hours of CE-
withdrawal (Fig 1G) significantly reduced CCL2, IL1β, and TNFα-mRNA increases
induced by the CE-withdrawal (Fig 8). The HMGB1 antagonist, glycyrrhizin (Ohnishi et al.
2011), also significantly reduced the increase in IL1β and TNFα-mRNAs that followed
withdrawal from CE-exposure, but did not significantly reduce the withdrawal-induced
increase in CCL2-mRNA (Fig 8).
The effect of the CRF1RA and HMGB1-antagonists on the increase in HMGB1-mRNA
increase following CE-withdrawal was also determined (Fig 9). The CRF1RA significantly
reduced the HMGB1-mRNA induced by CE-withdrawal. Likewise, ethyl-pyruvate also
significantly inhibited the HMGB1-mRNA increase by the CE-withdrawal; however,
glycyrrhizin caused only a non-significant reduction (p=0.094) in HMGB1-mRNA.
Collectively, these pharmacological strategies supported CRF and HMGB1 being involved
in the increased cytokine-mRNA and HMGB1-mRNA expressions observed following
withdrawal from the CE-protocol. 2857
DISCUSSION
To account for ethanol induction of cytokines in brain, Fernendez-Lizarbe et al. (2008)
suggested that ethanol, similar to LPS, causes a TLR4 accumulation in lipid-rafts to initiate
TLR4-signaling (see Introduction). LPS, a membrane component of bacteria (Erridge et al.,
2002), increases cytokines in brain, presumably by acting as a TLR4-agonist (Erridge et al.,
2002; Okun et al., 2009). However, Qin et al. (2007) reported that the LPS-induced
cytokine-mRNA induction in brain was based upon TNFα in blood entering brain to
contribute to the LPS-induced cytokine increase—a differing view. Thus, as compelling as
the lipid-raft hypothesis is for explaining the basis of TLR4-involvement in ethanol
increasing cytokines in brain (Fernendez-Lizarbe et al., 2008), the mechanism by which CE-
exposure involves TLR4 in the increase in cytokine-mRNAs in the sterile environment of
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brain remains unclear, particularly because ethanol is unlikely to directly act as an agonist
on TLR4s. Based upon the view that ethanol does not alter TLR4-function directly, this
investigation first undertook exploring for potential differences between the agonist action
of LPS on TLR4s with the acute and chronic actions of ethanol on mRNA-expression of
pro-inflammatory-cytokines and immune signaling proteins.
By comparing acute and chronic-ethanol and LPS-exposures, we gained valuable insight as
to the possible mechanism by which ethanol depends upon TLR4-signaling to increase brain
cytokines (see Introduction). An acute intoxicating dose of ethanol did not increase
cytokine-mRNAs in cortex of Sprague-Dawley rats 4-hours after administration—a finding
distinct from the several-fold increase in the cytokine-mRNAs observed 4-hours after acute-
LPS administration (Fig 2). Consistent with these findings, Buck et al. (2011) also found no
increase in IL-6 or IL1β-mRNAs in Sprague-Dawley rats 12-hours after ethanol (4g/kg).
However, Qin et al. (2008) reported in C57Bl/6 mice that a single 5g/kg oral dose of ethanol
increased TNFα- and CCL2-mRNAs in whole brain 24-hours after ethanol-dosing, without
a change IL1β-mRNA. Other than the differing species, whole-brain versus cortex, and/or
the higher dose of ethanol utilized, another possible reason for this distinction between
studies could in part relate to Sprague-Dawley rats being less sensitive than mice to
challenges which increase cytokine function (see Porterfield et al, 2011). While a significant
change in cytokine-mRNAs was lacking after acute-ethanol administration, CE-exposure
produced an approximate doubling of cytokine-mRNAs in cortex 24-hours after CE-
withdrawal. Distinct from this cytokine-mRNA increase by CE-withdrawal, chronic-LPS
produced no elevation in cortical cytokine-RNAs 24-hours after removal from LPS dosing—
a presumed reflection of the tachyphylaxis that occurs following repeated LPS-exposure
(Vartanian and Stenzel-Poore, 2010; West and Heagy, 2002; Ziegler–Heitbrock, 1995).
Thus, the present findings comparing acute- and chronic-ethanol to acute- and chronic-LPS
exposures provide clear evidence for a fundamental difference in the ability of LPS and
ethanol to influence neuroimmune-function in brain.
Previous studies in our lab established that CIE-exposure is more effective than exposure to
the CE-protocol at engendering anxiety-like symptoms during ethanol withdrawal (Breese et
al., 2011; Overstreet et al., 2002) or for increasing kindling of seizures (McCown and
Breese, 1990). Based on the possibility that CIE might produce a greater induction of
cytokine-mRNAs than the CE-exposure, these two CE-protocols were compared for their
ability to induce cytokine-mRNAs 24-hours following CE-withdrawal. The increase in
CCL2, IL1β, and TNFα cytokine-mRNAs observed after CE-withdrawal did not differ from
the cytokine-mRNA increase observed during withdrawal from the CIE-protocol. Thus,
unlike the “kindling” responsible for CIE-facilitation of withdrawal anxiety (Breese et al,
2005; 2011; Overstreet et al., 2002) and the kindling of seizures (McCown and Breese,
1990), cytokine-mRNA changes following the two CE-protocols were comparable. One
possible explanation for not observing a kindling-mediated difference between these CE-
protocols could be from having measured the elevation of cytokine-mRNAs only in cortex
—a site not associated with CIE-susceptibility for seizures (McCown and Breese, 1990) or
with facilitation of anxiety (Overstreet et al., 2002; Breese et al. 2011). Consequently, the
relationship between brain site and neuroimmune function after these differing CE-protocols
will need exploration in future investigations to resolve whether cytokine-mRNAs in
differing brain sites explain this lack of difference in cytokine-mRNA expression observed
by these differing CE-protocols.
Studies in whole-brain of C57Bl/6 mice found that 24-hours of ethanol abstinence from 10-
days of ethanol administration (5-gm/kg-IG/day) increased CCL2- and TNFα-mRNAs, but
not mRNAs for IL1-β or other cytokines (Qin et al., 2008). Whereas the CE-protocol
produced an increase in cytokine-mRNAs in cortex 24-hours after withdrawal, the time-
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course determination demonstrated that cytokine-mRNAs were not changed while still being
exposed to the CE-diet (T=0). Therefore, rather than just exposure to the CE-protocol, the
findings were a clear indication that the cytokine-mRNA increase associated with the CE-
protocol is not due to the chronic-ethanol exposure alone, but is dependent upon the 24-hour
withdrawal-period from the CE-exposure.
Given that the increase in cytokine-mRNAs induced by withdrawal from CE occurs in the
sterile environment of brain, a critical issue remained as to how this CE-withdrawal drives
this increased expression of cytokine-mRNAs. Therefore, based upon the documented
evidence for the TLR4 importance in ethanol’s action (see Introduction), mRNA levels
were determined for TLR4 as well for HMGB1, an endogenous TLR4-agonist (Andersson
and Tracey, 2011; Lin et al., 2005). Acute-ethanol caused no change in TLR4-mRNA, but
the CE- and CIE-protocols (Fig 7A) elevated TLR4-mRNA as well as HMGB1-mRNA
without affecting mRNAs for either MyD88- or NF-κB. Even though the HMGB1-mRNA
was nearly doubled following withdrawal from the CE-protocols, the HMGB1-mRNA prior
to removal from the CE-exposure (T=0) revealed at best only a small change—a time when
TLR4 and cytokine-mRNAs levels were not different from control. The TLR4- and
HMGB1-mRNAs peaked 24-hours after the withdrawal from the CE-protocol and gradually
fell to control level by 3-days and below the control levels by 7-days. The loss of the
HMGB1- and TLR4-mRNA temporal relationship with the cytokine-mRNAs by 7 days after
the removal from the CE-protocol days was certainly unexpected. Therefore, the biological
basis of this difference should be sought. Regardless, the increase in the HMGB1- and
TLR4-mRNAs having a temporal relationship with the elevated cytokine-mRNAs 24-hours
after CE-withdrawal was considered a critical clue for understanding how expression of
cytokine-mRNAs was increased during the CE-withdrawal.
From the demonstration that withdrawal from CE-exposure increased HMGB1-mRNA and
chronic-LPS did not, the possibility was considered that HMGB1 may be an endogenous
ligand released from neurons in brain (Faraco et al., 2007) during the CE-withdrawal that
would activate TLR4s to increase brain cytokine-mRNAs (Andersson and Tracy, 2011;
Faraco et al., 2007; Lin et al., 2012; Müller et al., 2001; Yang et al., 2005; Yu et al., 2006).
This intriguing presumption that HMGB1 release onto TLR4s contributes to the cytokine-
mRNA increases during CE-withdrawal was potentially consistent with various ethanol
actions being dependent upon TLR4 function (Alfonso-Loeches et al., 2010; Blanco et al.,
2005; Fernandez-Lizarbe et al., 2008; 2009; see Introduction). In support of this view,
Crews et al. (2012) observed that HMGB1-neutralizing antibodies added to brain slice
cultures blunted ethanol-induction of IL1β, a finding suggestive that this activation occurs
through a HMGB1/TLR-signaling mechanism. Nonetheless, because a CRF1RA prevents
facilitation of anxiety following CE-withdrawal (Breese et al., 2011; Knapp et al., 2004), the
possible involvement of CRF-release was also considered as a potential contributor to the
increase in cytokine-mRNAs during withdrawal from CE.
To test this hypothesis that HMGB1 and/or CRF support the cytokine-mRNA increase
induced by CE-withdrawal, antagonists for HMGB1 and CRF were administered twice
during the 24-hour period of withdrawal from the CE-protocol. The HMGB1-antagonists
utilized were glycyrrhizin (Faraco et al., 2007; Mollica et al., 2007; Ohnish et al., 2011) and
ethyl pyruvate (Davis et al., 2009; Su et al., 2011). The administration of the CRF1RA,
ethyl-pyruvate, and glycyrrhizin during the 24-hour period of CE-withdrawal all
significantly reduced the CCL2, IL1β and TNFα-mRNA increases that followed withdrawal.
Thus, these seminal findings clearly supported both HMGB1 and CRF being critical for the
increased expression of cytokine-mRNAs during the 24-hour withdrawal period that follows
exposure to the CE.
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The consequences of the CRF1RA and the HMGB1-antagonists were also tested against the
HMGB1-mRNA induction during withdrawal from the CE-protocol. Finding that the
CRF1RA and ethyl-pyruvate, but not glycyrrhizin, reduced the HMGB1-mRNA increase
that follows CE-withdrawal potentially provided further clarification of the potential
mechanism by which cytokine-mRNAs increase during withdrawal from the CE-protocol.
One interpretation from the outcome with the CRF1RA reduction of the HMGB1-mRNA
strongly suggests that the blockade of the action of CRF-released during CE-withdrawal is
controlling activation of HMGB1-mRNA—a mechanism which in turn prevents the
formation and release of HMGB1 to increase cytokine-mRNAs during the period of CE-
withdrawal (see Fig 8). However, in respect to the CRF1RA reduction in the expression of
HMGB1-mRNA, a degree of caution should be considered until established that this
antagonist does not have an influence on other distinct receptors associated directly with
brain neuroimmune-function. Regardless, an explanation for the ethyl-pyruvate preventing
HMGB1-release (Dave et al., 2009) to prevent the cytokine-mRNA increase following
withdrawal from the CE-protocol could relate to an intracellular action of this HMGB1-
antagonist preventing expression of HMGB1-mRNA. Based upon this mechanism proposed
for ethyl-pyruvate preventing HMGB1-release by minimizing further expression of
HMGB1-mRNA, a future study to critically test this view would seem warranted. On the
other hand, glycyrrhizin binding to HMGB1 (Girard, 2007; Mollica et al., 2007), while
blocking the increase in the cytokine-mRNAs, did not significantly alter the HMGB1-
mRNA increase induced by the withdrawal from the CE-protocol. Consequently, the present
data defining the distinct effects of ethyl-pyruvate and glycyrrhizin on HMGB1-mRNA
would seem consistent with mechanisms previously proposed for these HMGB1-antagonists
preventing HMGB1-action (Dave et al., 2009; Girard et al. 2007; Su et al., 2011). In
conclusion, the CRF1RA and HMGB1-antagonists preventing HMGB1 and CRF from
increasing cytokine-mRNAs induced by CE-withdrawal should be considered a first step in
clarifying the biological means by which neural and neuroimmune-processes can interact to
influence cytokine-mRNA expression in the sterile-milieu of brain. 4488
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Protocols for the experimental treatments described in this paper.
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Figure 2. Cytokine-mRNA and TLR4-mRNA expression following acute treatment with ethanol
(2.75 g/kg) and LPS (250 μg/kg)
(A) The acute single dose of 2.75 g/kg of ethanol I.P resulted in no significant increase in
cytokine-mRNAs for CCL2, IL1-β, or TNFα (all p>0.05). (B) The acute single 250 μg/kg
dose of LPS IP increased cytokine-mRNAs for CCL2, IL1-β, and TNFα four hours
following injection [(CCL2: t(17)=6.07, p<0.0001; IL1-β: t(16)=6.31, p<0.0001; TNFα:
t(13)=4.97, p=0.0003). Twenty-four hours after the acute dose of ethanol the levels of
cytokine-mRNAs were not significantly different from control P>0.05. Acute-ethanol (C)
and Acute LPS (D) treatments did not alter TLR4 mRNA expression either at four hours
(Fig C and D) or 24-hrs after their acute dosing (p>0.05). Thus, the acute ethanol exposure
did not recapitulate the increase in cytokine-mRNAs induced by acute LPS administration. *
Significantly different from control (p<0.05).
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Figure 3. Cytokine-mRNA expression following a chronic-ethanol-protocol (Fig 1.C) and a
chronic-LPS protocol (Fig 1D)
Twenty-four-hours after withdrawal from 15 days of 7% ethanol-diet (Chronic ethanol),
cytokine-mRNAs for CCL2, IL1-β, and TNFα are significantly increased compared to non-
treated controls (CD) (t(15)=4.53, p=0.0004; t(20)=3.42, p=0.0027; t(21)=5.443, p<0.0001,
respectively. In contrast, 24-hours after the chronic-LPS exposure cytokine-mRNAs for
CCL2, IL1-β, and TNFα were not significant increased (all cytokines = p>0.05). Again, the
CE- and chronic-LPS protocols differed in their expression of cytokine-mRNAs. *
Significantly different from Control (CD) (p<0.05).
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Figure 4. Effect of the chronic-ethanol protocol and chronic-LPS protocol on mRNAs for TLR4,
HMGB1, My88, and NFκB
(A). Chronic-ethanol significantly increased TLR4 mRNA expression [t(23)=2.669,
p=0.0137]. (B) Chronic-LPS (250 μg/kg/day for 10 days; Fig 1D) also significantly
increased TLR4 [t(18)=2.83, p=0.0112]. (C) Chronic-Ethanol significantly increased
HMGB1 mRNA exposure [t(16)=3.618, p=0.0023]. (D) Chronic-LPS was without effect on
mRNA for HMGB1 (p>0.05). (E-H) Chronic-ethanol and chronic-LPS did not significantly
affect either My88 (EF) or NF-κB (GH) mRNA levels (p>0.05). * Significantly different
from Control (p<0.05).
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Figure 5. Time course of changes for cytokine-mRNAs (top) and TLR4- and HMGB1-mRNAs
(bottom) while on (o-hr) and 24-hours after withdrawal from the CE-protocol
For cytokine-mRNAs (top), CCL2, IL1-β, and TNFα mRNAs significantly peaked 24-hours
after withdrawal from the CE-protocol compared to control [CCL2-mRNA = Control 100 ±
31.1 vs. CCL2 peak = 202.0 ± 33.3, p=0.025 (F(4,25)= 3.06, p=0.035]. [IL1-β-mRNA =
Control 100 ± 11.0 vs. IL1-β peak = 193.8 ± 38.9, p=0.0039) (F(4,27)= 5.05, p=0.036];
TNFα = Control 100 ± 9.3 vs. TNFα-Peak= 207.3 ± 38.7, p=0.0006) (F(4,27)=7.30;
p=0.0004]. At time t=0, cytokine-mRNAs were not significantly increased (p>0.05). The
peak expression of TLR4-mRNA 24-hours following withdrawal from the CE-protocol
(Bottom) was 218.7 ± 19.4 for TLR4 vs 100 ± 13.9 for control (F(4,27)=8.64, p=0.0001)
and 164.5 ± 15.6 for HMGB1 vs 100 ± 21.9 for the Control (F(2,26)=3.51, p=0.02). At T=0
(0 hr) TLR4 was not significantly different from control (p>0.05). However, while the
HMGB1-mRNA elevation at T=0 (0 hr) is significant, but only to a minor degree (p<0.05),
an additional investigation was unable to duplicate this significant increase [Control = 100 ±
16.4% vs HMGB1-mRNA = 120 ± 13.5%; p>0.05]. See text for descriptions of changes for
cytokine-mRNAs and the TLR4 and HMGB1-mRNAs 7 days after withdrawal from the CE-
protocol.
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Figure 6. Comparison of CE-protocol (Chronic ETOH; see Fig 1C) and Chronic-Intermittent
Ethanol (Cycled ETOH; see Fig 1F)
Twenty-four hours after removal from ethanol diet, both the Chronic Ethanol- and Cycled
Ethanol-treatment groups showed significant increases in CCL2, IL1-β, and TNFα-mRNA
[F(2,18)= 5.211, p=0.018; F(2,24)=9.718, p=0.0009; F(2,25)=6.475, p=0.006, respectively].
However, a statistical difference did not occur between the cytokine-mRNAs for the Chronic
ETOH and Cycled ETOH-treatment groups (p>0.05). * Significantly different from Control
(p<0.05).
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Figure 7. Comparison of CE- and cycled-ethanol treatment groups on mRNAs for TLR4,
HMGB1, MyD88 and NF-κB
(A) TLR4 was significantly elevated in both the chronic and cycled ethanol groups
(F(2,23)=8.744, p=0.0017); However, a difference between the chronic and cycled groups
was not observed (p>0.05). (B) Both the chronic and cycled ethanol protocol groups
significantly elevated HMBG1-mRNA (F(2,24)=3.787, p=0.0466), but no difference
between the chronic- and cycled-ethanol protocols was noted (p>0.05). (C&D) Neither the
chronic nor the cycled ethanol protocol groups caused a discernible effect on levels of
MyD88 or NF-κB p>0.05). * Significantly different from CD (p<0.05).
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Figure 8. Testing of a CRF1RA [CP154,526 (CP: 10 mg/kg)] or the HMGB1 antagonists,
glycyrrhizin (Gly: 50 mg/kg) and ethyl-pyruvate (EP: 75 mg/kg), on the cytokine-mRNA
increases induced by 24-hrs of withdrawal (WD) from CE-exposure. Each drug was
administered at 3 and 12 hours into the withdrawal period after cessation of ethanol diet
exposure
There were significant group effects for each mRNA [TNFα = F(4, 37) = 6.16, p<0.05; IL1β
= F(4,37) = 3.46, p<0.05; and CCL2 = F(4,42) = 4.28, p<0.05]. TNFα, CCL2, & IL1β-
mRNAs were significantly elevated 24-hours after withdrawal from the CE-24h-WD
protocol (P<0.05), in accord with results in Fig 3. The CRF1 receptor antagonist CP154,526
(CP: 10 mg/kg) and ethyl-pyruvate (EP: 75 mg/kg) significantly reduced the cytokine
mRNA increases for TNFα and IL1β 24-hours after removal from the CE-protocol (p<0.05).
After the HMGB1 inhibitor, glycyrrhizin (Gly: 50 mg/kg), the suppression of CCL2-mRNA
from the CE-24-WE-veh did not reach statistical significance (p=0.059).
*Significantly different from CE-24h-WD (p<0.05).
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Figure 9. Testing of the CRF1-receptor antagonist CP154,526 (CP: 10 mg/kg) or the HMGB1-
antagonists, glycyrrhizin (Gly: 50 mg/kg) and ethyl-pyruvate (EP: 75 mg/kg), on the HMGB1-
mRNA increase induced by withdrawal (WD) from chronic ethanol (CE)-exposure
See Figure 8 for further details. Overall effect of groups was significant, [F(4,41) = 3.96,
p<0.05]. The CRF1 receptor antagonist [CP154,526 (CP: 10 mg/kg)] and ethyl-pyruvate
(EP: 75 mg/kg) significantly reduced the HMGB1-mRNA increase after removal from the
CE-24-WD-protocol (p<0.05). The trend toward suppression of HMGB1 with glycyrrhizin
after the CE-24-WD protocol did not reach statistical significance (p=0.094).
* Significantly different from CE-24h-WD (p<0.05).
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Table 1
Primer sequences
CCL2 5′-TCACGCTTCTGGGCCTGTTG-3′ (forward)5′-CAGCCGACTCATTGGGATCATC-3′ (reverse)
IL1-β 5′-GAAACAGCAATGGTCGGGAC-3′ (forward)5′-AAGACACGGGTTCCATGGTG-3′ (reverse)
TNFα 5′-ATGTGGAACTGGCAGAGGAG-3′ (forward)5′-ACGAGCAGGAATGAGAAGAGG-3′ (reverse)
TLR4 5′-GCCGGAAAGTTATTGTGGTGGT-3′ (forward)5′-ATGGGTTTTAGGCGCAGAGTTT-3′ (reverse)
NF-κB 5′-GGCAGCACTCCTTATCAA-3′ (forward)5′-GGTGTCGTCCCATCGTAG -3′ (reverse)
MyD88 5′-GGCAGGCTGCTAGAGTTGCT -3′ (forward)5′-TGTGGGACACTGCTCTCCAC-3′ (reverse)
HMGB1 5′-GAGATCCTAAGAAGCCGAGA-3′ (forward)5′-CTTCCTCATCCTCTTCATCC-3′ (reverse)
β-actin 5′-ATGGTGGGTATGGGTCAGAAGG-3′ (forward)5′-GCTCATTGTAGAAAGTGTGGTGCC-3′ (reverse)
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Table 2
Acute-Ethanol or Acute-LPS on CCL2, IL1β, and TNFα-Peptides.
Treatment CCL2 IL1β TNFα
Water (n) 29.03 +/− 1.11 1.12 +/− 0.04 0.15 +/− 0.04
Ethanol (n) 27.01 +/− 0.78 1.15 +/− 0.03 0.37 +/− 0.04*
Saline (n) 34.49 +/− 1.94 0.81 +/− 0.06 0.30 +/− 0.01
LPS (n) 196.96 +/− 20.55** 9.33 +/− 1.38*** 0.28 +/− 0.03
Data from cerebral cortex are mean +/− SEM of cytokine-peptides/mg total protein. Acute-LPS (lipopolysaccharide) (250 ug/kg; n = 8) on CCL2 =
Chemokine (C-C motif) ligand 2; IL1β = Interleukin-1β; TNFα = Tumor Necrosis Factor-α. Water and ethanol (2.75 g/kg) were administered
intragastrically (n = 4 and 8, respectively). Saline and LPS were administered IP (n = 8 for both). TNFα:
*
t(10) = 3.88, p<0.005 vs water;
**
CCL2: t(14) = 7.87, p< 0.0001 vs saline;
***
IL1β: t(14) = 6.14, p<0.0001 vs Saline.
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Table 3
CCL2 , IL1β, and TNFα-Peptides 24-hours after Withdrawal from CE-Exposure.
Treatment CCL2 IL1β TNFα
Control Diet 34.5 +/− 1.9 (8) 1.14 +/− 0.11 (8) 0.38 +/− 0.07 (8)
CE-24-Hr after
Withdrawal 36.7 +/− 1.8 (16) 1.01 +/− 0.08 (10) 0.32 +/− 0.04 (9)
Data from cerebral cortex are mean +/− SEM of cytokine-peptides/mg total protein (n=number). CE = Chronic ethanol exposure. See Methods for
Control Diet. CE-24-hr after withdrawal = Rats being removed for 24 hrs from the CE-exposure (see Methods)
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